UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Sphingolipids in essential hypertension and endothelial dysfunction
Spijkers, L.J.A.
Publication date
2013
Link to publication
Citation for published version (APA):
Spijkers, L. J. A. (2013). Sphingolipids in essential hypertension and endothelial dysfunction.
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s)
and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open
content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please
let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material
inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter
to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You
will be contacted as soon as possible.
Stellingen behorende bij het proefschrift:
“Sphingolipids in essential hypertension and endothelial dysfunction”
1. Ceramide forms both a biological marker for hypertension as well as a therapeutic target for hypertension-associated endothelial dysfunction. [This dissertation]
2. Elevated ceramide levels are not sufficient on their own to substantially increase vascular resistance. [This dissertation]
3. Ceramide-induced vascular contraction contributes primarily to systolic rather than diastolic hypertension.[This dissertation]
4. Appointing ‘ceramide’ as a contributive factor to the onset of
endothelial dysfunction is equally inaccurate as describing the pathophysiological mechanism in ‘the hypertensive patient’.
[This dissertation]
5. In the end it’s just fat that determines our form, functioning and fate. [This dissertation]
6. Genomics and proteomics proved to be fundamental to therapeutic target finding but insufficient to avoid the Innovation Gap in drug discovery; it’s lacking sphingolipidomics! [This dissertation]
7. It is always the new therapeutic target that gleams most invitingly, because we lack any knowledge about efficacy and safety, seeing only the seductive promise of advances in understanding and application in medicine. [Prof. Dr Hugh Rosen]
8. Treating hypertension is not just about lowering blood pressure, it is more about quantifying and reducing cardiovascular disease risk. [Prof. Dr Bryan Williams]
9. With hypertension, the reward for treatment comes 20 years later and there are no positive measures of reward, only negative measures. [Prof. Dr Giuseppe Mancia]
10. We all make choices, but in the end our choices make us. [Andrew Ryan]
11. Life is one big experiment. I’m studying the beneficial effects of wine consumption on cardiovascular health. For this I prefer wine of high quality; not for scientific reasons, life’s just too short to drink bad wine. 12. Founding a family follows a simple statistical rule-of-thumb; N=2 can
